Literature DB >> 16328428

Vesicular stomatitis virus induces apoptosis in the Wong-Kilbourne derivative of the Chang conjunctival cell line.

Eva Gallyas1, György Seprényi, Eniko Sonkoly, Yvette Mándi, Lajos Kemény, Klára Megyeri.   

Abstract

BACKGROUND: Virotherapy represents a novel therapeutic modality for the treatment of malignant diseases. Vesicular stomatitis virus (VSV) has been shown to exert antitumor effect in several tumor types. Since the potential oncolytic activity of VSV has not yet been evaluated in epithelial tumors of the conjunctiva, we set out to investigate the susceptibility of the immortalized Wong-Kilbourne derivative of the Chang conjunctival cell line (WK) to VSV and analyze the role of apoptosis in VSV-mediated induction of cell death.
METHODS: WK cells were infected with VSV at various multiplicities and maintained for different periods of time. VSV-infected cells were analyzed by inverted microscopy for the development of cytopathic effects (CPE). Virus replication was measured by indirect immunofluorescence assay, Western blot analysis and plaque titration. The apoptotic response of the infected cells was quantitated by ELISA detecting the enrichment of nucleosomes in the cytoplasm. Western blot analysis was used to determine the levels of Bcl-2 and Bax proteins.
RESULTS: The WK cell line was highly permissive to VSV replication and was highly susceptible for the CPE of this virus. VSV infection elicited the apoptotic death of WK cells. Mock-infected cells exhibited endogenous expression of Bcl-2 and p21 Bax proteins. VSV infection caused a significant decrease in the expression level of Bcl-2. Moreover, in parallel with a slight decrease in the level of p21 Bax, p18 Bax protein accumulated in VSV-infected WK cells.
CONCLUSIONS: VSV is a powerful inducer of apoptosis in immortalized WK cells. The VSV-mediated alterations in the expressions of Bcl-2 and Bax proteins may play important roles in the apoptotic responses of infected cells and may also sensitize to other apoptotic stimuli. This virus may possess oncolytic activity in epithelial tumors of the conjunctiva.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16328428     DOI: 10.1007/s00417-005-0162-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  36 in total

1.  Replication-selective microbiological agents: fighting cancer with targeted germ warfare.

Authors:  D H Kirn
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  The p18 truncated form of Bax behaves like a Bcl-2 homology domain 3-only protein.

Authors:  Pierre-François Cartron; Lisa Oliver; Philippe Juin; Khaled Meflah; François M Vallette
Journal:  J Biol Chem       Date:  2003-12-17       Impact factor: 5.157

3.  Comparison of morphological and functional characteristics of primary-cultured human conjunctival epithelium and of Wong-Kilbourne derivative of Chang conjunctival cell line.

Authors:  M De Saint Jean; C Baudouin; M Di Nolfo; S Roman; P Lozato; J M Warnet; F Brignole
Journal:  Exp Eye Res       Date:  2004-02       Impact factor: 3.467

4.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

Authors:  Anthony Letai; Michael C Bassik; Loren D Walensky; Mia D Sorcinelli; Solly Weiler; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

5.  Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease.

Authors:  Marilyn Fernandez; Mercedes Porosnicu; Dubravka Markovic; Glen N Barber
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus.

Authors:  Katsunori Shinozaki; Oliver Ebert; Chryssanthi Kournioti; Yun-Sheng Tai; Savio L C Woo
Journal:  Mol Ther       Date:  2004-03       Impact factor: 11.454

7.  Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2.

Authors:  S Krajewski; M Krajewska; A Shabaik; T Miyashita; H G Wang; J C Reed
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

8.  Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.

Authors:  Masatsugu Obuchi; Marilyn Fernandez; Glen N Barber
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 9.  Tumors of the conjunctiva and cornea.

Authors:  Carol L Shields; Jerry A Shields
Journal:  Surv Ophthalmol       Date:  2004 Jan-Feb       Impact factor: 6.048

Review 10.  Vesicular stomatitis virus: re-inventing the bullet.

Authors:  Brian D Lichty; Anthony T Power; David F Stojdl; John C Bell
Journal:  Trends Mol Med       Date:  2004-05       Impact factor: 11.951

View more
  2 in total

1.  Proteomic analyses of gastric cancer cells treated with vesicular stomatitis virus matrix protein.

Authors:  Dequan Zeng; Tao Zhang; Shengtao Zhou; Hao Hu; Jingyi Li; Kai Huang; Yunlong Lei; Kui Wang; Yong Zhao; Rui Liu; Qiu Li; Yanjun Wen; Canhua Huang
Journal:  Protein J       Date:  2011-06       Impact factor: 2.371

2.  Comparison of gene expression profiles of conjunctival cell lines with primary cultured conjunctival epithelial cells and human conjunctival tissue.

Authors:  Louis Tong; Yolanda Diebold; Margarita Calonge; Jianping Gao; Michael E Stern; Roger W Beuerman
Journal:  Gene Expr       Date:  2009
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.